Home » Stocks » XBIO

Xenetic Biosciences, Inc. (XBIO)

Stock Price: $1.67 USD 0.10 (6.37%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 14.26M
Revenue (ttm) 571,409
Net Income (ttm) -11.06M
Shares Out 8.75M
EPS (ttm) -1.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $1.67
Previous Close $1.57
Change ($) 0.10
Change (%) 6.37%
Day's Open 1.61
Day's Range 1.57 - 1.69
Day's Volume 49,122
52-Week Range 0.76 - 5.85


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Continued Execution on Xcart™ Development Plan With Commencement of Exploratory Patient Biopsy Trial Expected To Position the Company To Conduct Ind-Enabling Studies in the United States Licensing Partn...

2 days ago - Accesswire

Live video webcast with CEO, Jeffrey Eisenberg on Tuesday, May 18, 2021 at 3:30 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 10, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a...

4 days ago - Accesswire

- Data from the study to provide valuable insights as the Company advances XCART lead program in Non-Hodgkin lymphoma (NHL) towards Investigational New Drug (IND) filing in the United States - Study wil...

1 month ago - Accesswire

Driving development of XCART™ platform and leveraging academic collaborations through preclinical development Recent clinical, regulatory and commercial advancements from licensing partners leveraging P...

1 month ago - Accesswire

FRAMINGHAM, MA / ACCESSWIRE / March 3, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform...

2 months ago - Accesswire

FRAMINGHAM, MA / ACCESSWIRE / January 14, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platf...

4 months ago - Accesswire

FRAMINGHAM, MA / ACCESSWIRE / January 5, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platfo...

4 months ago - Accesswire

Shares of Xenetic Biosciences Inc (NASDAQ: XBIO), a drug delivery platform company, were ripping higher Wednesday on markedly above-average volume. What Happened: The Framingham, Massachusetts-based com...

5 months ago - Benzinga

Shares of Xenetic Biosciences Inc. skyrocketed on massive volume toward a 17-month high in morning trading Wednesday, after the Massachusetts-based biopharmaceutical company said its partner PJSC Pharms...

5 months ago - Market Watch

The stock price of Xenetic Biosciences, Inc. (NASDAQ:XBIO) are trading at over 300% as it went from $1.08 in the previous close to $4.88 as of 11:17 AM ET. This is why it happened.

5 months ago - Pulse2

Xenetic Biosciences (XBIO) news for Wednesday includes positive news from a Phase 3 clinical trial boosting XBIO stock higher. The post Xenetic Biosciences News: Why XBIO Stock Is Going Ballistic Today ...

5 months ago - InvestorPlace

Nano-cap biotech Xenetic Biosciences Inc.'s stock was rallying Friday following an announcement concerning pricing for its previously announced offering of common stock and accompanying warrants.

1 year ago - Benzinga

About XBIO

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, ... [Read more...]

Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2020, XBIO's revenue was $436,942, an increase of 2,460.31% compared to the previous year's $17,066. Losses were -$10.89 million, -14.73% less than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for XBIO stock is "Buy." The 12-month stock price forecast is 5.00, which is an increase of 199.40% from the latest price.

Price Target
(199.40% upside)
Analyst Consensus: Buy